CLINICAL LIPIDOLOGY. A COMPANION TO BRAUNWALD'S HEART DISEASE. 3RD EDITION

• SECTION I INTRODUCTION/BASIC MECHANISMS
1 Overview of Lipids and Atherosclerosis
• SECTION II RISK ASSESSMENT
2 Overview of Risk Assessment
3 Measurement of Low- Density Lipoprotein
Cholesterol, Non-High- Density Lipoprotein
Cholesterol, Apolipoprotein B, and
Low- Density Lipoprotein Particle
Concentration
4 Triglycerides, Triglyceride- Rich Lipoproteins,
and High- Density Lipoprotein in Coronary
Heart Disease Risk Assessment
5 Lipoprotein(a) in Cardiovascular Risk
Assessment
6 Clinical Evaluation for Genetic Testing and
Secondary Causes of Dyslipidemia
7 Polygenic Risk Scores
8 High- Sensitivity C- Reactive Protein
9 Emerging Assays for Risk Assessment
10 Imaging Atherosclerosis for Risk
Stratifi cation: Cardiac Computed
Tomography and Carotid Ultrasound
• SECTION III THERAPY
11 Overview of General Approach to
Management of Dyslipidemias
12 Treatment Guidelines Overview: American
Heart Association/American College of
Cardiology/Multisociety Guideline and
Updates
13 Treatment Guidelines Overview:
European Society of Cardiology/European
Atherosclerosis Society Guidelines
14 Dietary Patterns for the Prevention and
Treatment of Cardiovascular Disease
15 Updated Clinical Guide to Exercise and
Lipids
16 Obesity, Lipids, and Cardiovascular Disease
17 Statins
18 Cholesterol Absorption Inhibitors
19 Omega- 3 Fatty Acids
20 Proprotein Convertase Subtilisin/Kexin Type
9 Inhibition
21 Inclisiran
22 Bempedoic Acid
23 Pemafi brate: A New Selective Peroxisome
Proliferator-Activated Receptor- _
Modulator for Hypertriglyceridemia
Management
24 Anti- inflammatory Therapy for
Cardiovascular Disease
25 Nutraceuticals and Functional Foods for
Cholesterol Reduction
• SECTION IV NEW AND EVOLVING THERAPEUTIC TARGETS AND PLATFORMS
26 Evolving Therapeutic Targets:
Lipoprotein(a)
27 Inhibition of ANGPTL3 as a Target for
Treating Dyslipidemias
28 Evolving Therapeutic Targets:
Apolipoprotein C- III
29 Evolving Therapeutic Targets: Cholesteryl
Ester Transfer Protein Inhibition
30 Gene Therapy and Therapeutic Genome
Editing in Liver for Lipid Disorders
• SECTION V SPECIAL PATIENT POPULATIONS
31 Special Patient Populations: Diabetes and
Metabolic Syndrome
32 Special Patient Populations: Women and
Older Adults
33 Special Patient Populations: Children and
Adolescents
34 Special Patient Populations: Familial
Hypercholesterolemia and Other Severe
Hypercholesterolemias
35 Special Patient Populations: Treatment of
Familial Chylomicronemia Syndrome and
Sustained Chylomicronemia
36 Special Patient Populations: Acute Coronary
Syndromes
37 Special Patient Populations: Transplant
Recipients
38 Special Populations: Chronic Kidney
Disease
39 Special Patient Populations: Lipid
Abnormalities in High- Risk Racial/Ethnic
Groups
40 Persons With Human Immunodeficiency
Virus

Part of the renowned Braunwald family of references, Clinical Lipidology: A Companion to Braunwald’s Heart Disease provides today’s clinicians with clear, authoritative guidance on the therapeutic management of patients with high cholesterol levels and other atherogenic lipid disorders. An invaluable resource for cardiologists, lipidologists, endocrinologists, and internal medicine physicians, this one-stop reference covers everything from basic science and the pathogenesis of atherothrombotic disease to risk assessment and the latest therapy options. Now fully updated from cover to cover, the 3rd Edition offers unparalleled coverage of lipidology in an accessible and user-friendly manner.

Author
Christie M. Ballantyne, MD, FACP, FACC, Chief, Section of Cardiology, Chief, Section of Cardiovascular Research, Professor of Cardiovascular Medicine, Baylor College of Medicine, Houston, Texas